Today, a Director at OncoSec Medical (ONCS), James Demesa, bought shares of ONCS for $6,965.
This recent transaction increases James Demesa’s holding in the company by 154.52% to a total of $19.95K. In addition to James Demesa, one other ONCS executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, OncoSec Medical has an average volume of 42.49K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.
Read More on ONCS:
